Solid Malignancies clinical trials at UCSF
2 research studies open to eligible people
Solid malignancies are cancers that make solid growths in organs or tissues. UCSF is testing the antibody GIM-122 for safety in advanced solid tumors. UCSF is also testing AZD9574 alone and with other drugs to study tolerability and drug levels in the body.
AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
open to eligible people ages 18-130
This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in participants with advanced cancer that has recurred/progressed.
San Francisco, California and other locations
GIM-122 in Subjects With Advanced Solid Malignancies
open to eligible people ages 18 years and up
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
San Francisco, California and other locations
Our lead scientists for Solid Malignancies research studies include Katy Tsai, MD.
Last updated: